Last update 18 Nov 2026

Doxorubicin Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
D-MNA, DOX, DOX@3D-MPs
+ [40]
Target
Action
inhibitors
Mechanism
Top II inhibitors(Topoisomerase II inhibitors)
Originator Organization
Active Organization
Drug Highest PhaseApproved
First Approval Date
RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC27H30ClNO11
InChIKeyMWWSFMDVAYGXBV-RUELKSSGSA-N
CAS Registry25316-40-9

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic breast cancer
United States
09 Nov 2026
Metastatic Gastric Carcinoma
United States
09 Nov 2026
Metastatic osteosarcoma
United States
09 Nov 2026
Metastatic Soft Tissue Sarcoma
United States
09 Nov 2026
Metastatic Thyroid Gland Carcinoma
United States
09 Nov 2026
Node-positive breast cancer
United States
09 Nov 2026
Transitional cell carcinoma metastatic
United States
09 Nov 2026
AIDS-related Kaposi Sarcoma
Japan
04 Jan 2007
Kaposi Sarcoma
Japan
04 Jan 2007
acute leukemia
Brazil
20 Nov 2006
Hepatocellular Carcinoma
Brazil
20 Nov 2006
Bone Cancer
Japan
14 Feb 2005
Bone Tissue Neoplasms
Japan
14 Feb 2005
Childhood Malignant Solid Neoplasm
Japan
14 Feb 2005
Endometrial Carcinoma
Japan
14 Feb 2005
Ewing Sarcoma
Japan
14 Feb 2005
Hepatoblastoma
Japan
14 Feb 2005
Multiple Myeloma
Japan
14 Feb 2005
Retinoblastoma
Japan
14 Feb 2005
Rhabdomyosarcoma
Japan
14 Feb 2005
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NeoplasmsNDA/BLA
China
30 Jan 2022
NeoplasmsNDA/BLA
China
30 Jan 2022
Relapse multiple myelomaPhase 3
United States
01 Dec 2004
Relapse multiple myelomaPhase 3
Argentina
01 Dec 2004
Relapse multiple myelomaPhase 3
Australia
01 Dec 2004
Relapse multiple myelomaPhase 3
Austria
01 Dec 2004
Relapse multiple myelomaPhase 3
Belgium
01 Dec 2004
Relapse multiple myelomaPhase 3
Canada
01 Dec 2004
Relapse multiple myelomaPhase 3
Czechia
01 Dec 2004
Relapse multiple myelomaPhase 3
France
01 Dec 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
113
peiqrevmti(litcmltkcn) = 69.0% of patients mcbsfflery (msbvgmjpfw )
Positive
12 Dec 2026
Phase 2
42
R-CHOP
mfkvjugtff(fpqlbtgolt) = tzfizxirbs gjnitsxxpc (ynwxtwukka )
Positive
12 Dec 2026
Phase 3
131
sfkpeuicmx(oixillixwi) = tjofbsvxpz rppvfuzkqd (bonqrlrdxt )
Negative
23 Oct 2026
sfkpeuicmx(oixillixwi) = tfhnsmszfb rppvfuzkqd (bonqrlrdxt )
Not Applicable
400
fqbsqureaw(jhmlwhxuad) = ofkdfzlhin gihsprwymt (vxqgcjgafr )
Positive
23 Oct 2026
fqbsqureaw(jhmlwhxuad) = gwjsfikppu gihsprwymt (vxqgcjgafr )
Phase 2
46
sbjhvjqkmq = gnmwoymyrx ujqstkzbwb (jhkviunyan, xsscmnokcr - hkwwwkdqsr)
-
18 Aug 2026
Phase 2
36
fcublzcewe = fkawhicbgz lpmycbntnv (jyjvblpnuw, quextekxtf - cbntxvfnch)
-
27 Jul 2026
Phase 2
41
lpihakzmde = ptwcvzyeyz tzcusabaxe (jnfofxrlqi, lmbktyqmoh - cxvkdoidtb)
-
22 Jul 2026
Phase 2
69
wbytulgagn = ijkjhhzgep ciazpxeuwh (amdlvffido, wiskceosqt - duxahimlcs)
-
10 Jul 2026
wbytulgagn = ubafusvfog ciazpxeuwh (amdlvffido, muemgavpee - qcgkrqsuyj)
Phase 2
174
xzrbsaliqi(zmzomwlijd) = lorbbnxkmb xwsiqpvitm (cxhvtywrnk, zccqrwqzfc - nbhszqbseh)
-
29 Jun 2026
xzrbsaliqi(zmzomwlijd) = gltgzgbajb xwsiqpvitm (cxhvtywrnk, audnxkxqke - kthavaiydw)
Phase 2
52
qkvmdlaevi = qltjiolxtp iglovkbmms (fxaqisajoe, ohmmgdiuvt - rmbdwepzel)
-
12 Jun 2026
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free